Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Dermatology Drugs Market 

5.1. COVID-19 Landscape: Dermatology Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Dermatology Drugs Market, By Indication

8.1. Dermatology Drugs Market, by Indication, 2024-2033

8.1.1 Acne

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Psoriasis

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Rosacea

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Alopecia

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Dermatology Drugs Market, By Distribution Channel

9.1. Dermatology Drugs Market, by Distribution Channel, 2024-2033

9.1.1. Hospital Pharmacies

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Retail Pharmacies

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Online Pharmacies

Chapter 10. Global Dermatology Drugs Market, By Administration Analysis 

10.1. Dermatology Drugs Market, by Administration Analysis, 2024-2033

10.1.1. Topical Administration

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Oral Administration

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Parenteral Administration

Chapter 11. Global Dermatology Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Indication (2021-2033)

11.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.1.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Indication (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Indication (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Indication (2021-2033)

11.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Indication (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Indication (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Indication (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Indication (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Indication (2021-2033)

11.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Indication (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Indication (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Indication (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Indication (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Indication (2021-2033)

11.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Indication (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Indication (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Indication (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Indication (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Indication (2021-2033)

11.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Indication (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Indication (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)

Chapter 12. Company Profiles

12.1. LUPIN (India)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis AG (Switzerland)

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. F. Hoffmann-La Roche Ltd (Switzerland)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Pfizer Inc. (U.S.)

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Sanofi (France)

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Amgen inc. (U.S.)

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Lilly (U.S.)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. AstraZeneca (U.K.)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. AbbVie Inc (U.S.)

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Johnson & Johnson Private Limited (U.S.)

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

 

14.2. Glossary of Terms